+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Primaquine radical cure of Plasmodium vivax: a critical review of the literature



Primaquine radical cure of Plasmodium vivax: a critical review of the literature



Malaria Journal 11: 280



Primaquine has been the only widely available hypnozoitocidal anti-malarial drug for half a century. Despite this its clinical efficacy is poorly characterized resulting in a lack of consensus over the optimal regimen for the radical cure of Plasmodium vivax. Published studies since 1950 of the use of primaquine regimens for preventing P. vivax relapse were reviewed. Data were extracted systematically from available papers. Primaquine regimens were categorized according to the total dose administered: very low (≤2.5 mg/kg), low (>2.5 mg/kg- < 5.0 mg/kg) and high (≥ 5.0 mg/kg). The risk of recurrent infection were summarized across geographical regions and the odds ratios between treatment regimens calculated after stratifying by total treatment dose and duration of study follow up. Data could be retrieved from 87 clinical trials presenting data in 59,735 patients enrolled into 156 treatment arms, conducted in 20 countries. There was marked heterogeneity in study design, particularly primaquine dosing and duration of follow up. The median rate of recurrence following very low dose of primaquine (n = 44) was 25% (range 0-90%) at 4-6 months, compared to 6.7 % (range 0-59%) following low dose primaquine (n = 82). High dose primaquine regimens were assessed in 28 treatment arms, and were associated with a median recurrence rate of 0% (Range: 0-15%) at one month. In 18 studies with control arms, the effectiveness of a very low dose primaquine regimen was no different from patients who did not receive primaquine (OR = 0.60, 95%CI 0.33-1.09, p = 0.09), whereas for the low dose regimens a significant difference was reported in 50% (6/12) of studies (overall OR = 0.14, 95%CI: 0.06-0.35, p < 0.001). Two studies enrolling 171 patients demonstrated high effectiveness of high dose primaquine compared to a control arm (OR = 0.03 (95%CI: 0.01-0.13); p < 0.0001). Low dose regimens retain adequate efficacy in some areas, but this is not uniform. The efficacy and safety of pragmatic high dose primaquine regimens needs to be assessed in a range of endemic and geographical locations. Such studies will require a prolonged period of follow up and comparison with control arms to account for confounding factors.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055172737

Download citation: RISBibTeXText

PMID: 22900786

DOI: 10.1186/1475-2875-11-280


Related references

Primaquine for radical cure of Plasmodium vivax and Plasmodium ovale malaria: an observational survey (2008-2010). Journal of Travel Medicine 20(2): 134-136, 2013

Expanding the Use of Primaquine for the Radical Cure of Plasmodium vivax. Clinical Infectious Diseases 67(7): 1008-1009, 2018

Optimal primaquine use for radical cure of Plasmodium vivax and Plasmodium ovale malaria in Japanese travelers--A retrospective analysis. Travel Medicine and Infectious Disease 13(3): 235-240, 2016

Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivax. Acta Tropica 160: 35-38, 2016

Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. American Journal of Tropical Medicine and Hygiene 62(3): 393-395, 2000

A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. American Journal of Tropical Medicine and Hygiene 82(4): 542-547, 2010

Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. Bmc Medicine 13: 294, 2015

Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. International Ophthalmology 39(8): 1767-1782, 2019

Primaquine; a new drug for the radical cure of relapsing vivax malaria. Journal of the Medical Association of Georgia 41(4): 126, 1952

Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon. American Journal of Tropical Medicine and Hygiene 82(6): 1017-1023, 2010

Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. American Journal of Tropical Medicine and Hygiene 26(3): 562-563, 1977

Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. Plos Neglected Tropical Diseases 12(4): E0006440, 2018

Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malaria Journal 16(1): 141, 2017

Implementation of G6PD testing and primaquine for P. vivax radical cure: Operational perspectives from Thailand and Cambodia. Who South-East Asia Journal of Public Health 6(2): 60-68, 2017

Prophylactic efficacy of primaquine for preventing Plasmodium falciparum and Plasmodium vivax parasitaemia in travelers: A meta-analysis and systematic review. Travel Medicine and Infectious Disease 17: 5, 2017